| Title: | Lipoprotein (a) in the Full Spectrum of MASLD; Evidence from Histologically and Genetically Characterized Cohorts |
| Journal: | Clinical Gastroenterology and Hepatology |
| Published: | 11 Dec 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39672249/ |
| DOI: | https://doi.org/10.1016/j.cgh.2024.10.018 |
Publication 14700
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND & AIMS: Lipoprotein(a) (Lp(a)) is an emerging biomarker for cardiometabolic factors. We studied the role of Lp(a) in the full spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD).</p>
METHODS: Three independent analyses were implemented using a multi-center, cross-sectional, liver biopsy-based study (n = 332) (Study 1) and the UK Biobank prospective study (n = 270,004) (Study 2; median follow-up, 12.47 years). In Study 1, we studied the cross-sectional association between Lp(a) mass and MASLD stages (Analysis A). In Study 2, we studied the prospective association between Lp(a) concentration and MASLD, liver cirrhosis, and hepatocellular carcinoma (Analysis B). Finally, these analyses were accompanied by a prospective analysis using LPA Genetic Risk Score (Analysis C).</p>
RESULTS: In Study 1, an inverse association between Lp(a) and at-risk metabolic dysfunction-associated steatohepatitis (odds ratioper 1-SD increase, 0.64; 95% confidence interval [CI], 0.42-0.97) was observed. In contrast, when similar associations were examined prospectively (Study 2), subjects with Lp(a) <10.75 nmol/L had a higher risk for cirrhosis (hazard ratio, 1.49; 95% CI, 1.22-1.81) and HCC (hazard ratio, 1.69; 95% CI, 1.12-2.56) compared with subjects with Lp(a) within the 10.75 to 21.5 nmol/L range. Above these levels, the risk increased significantly and positively. Similarly, genetic analysis showed an L-shaped association with LPA Genetic Risk Score.</p>
CONCLUSIONS: The inverse association observed in cross-sectional studies should be attributed to reverse causality (ie, the presence of liver disease may decrease Lp(a) levels). Genetically predicted very low Lp(a) levels are also associated with impaired liver health prospectively. Clinical trials evaluating Lp(a)-lowering agents should thus be monitored carefully for adverse liver effects in subjects attaining extremely low concentrations.</p>
10 Authors
- Hong Fan
- Matina Kouvari
- Geltrude Mingrone
- Jacob George
- Georgios Papatheodoridis
- Laura Valenzuela-Vallejo
- Zhenqiu Liu
- Xingdong Chen
- Tiejun Zhang
- Christos S Mantzoros
1 Application
| Application ID | Title |
|---|---|
| 63726 | Genetic and Biomarker Data Improve Risk Prediction for Gastrointestinal Cancer in large Population Studies |
Enabling scientific discoveries that improve human health